Drug Profile
OCU 100
Alternative Names: LEDGF-1-326; OCU-100; recombinant LEDGF1-326 - OcugenLatest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator University of Colorado at Anschutz Medical Campus
- Developer Ocugen
- Class Biological proteins; Eye disorder therapies; Peptide fragments
- Mechanism of Action Signal transducing adaptor protein modulators; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Retinitis pigmentosa
Most Recent Events
- 17 Mar 2022 Discontinued - Preclinical for Retinitis pigmentosa in USA (unspecified route) prior to March 2022 (Ocugen pipeline, March 2022)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA
- 01 Jan 2019 OCU 100 receives Orphan Drug status for Retinitis pigmentosa in European Union before January 2019 (Ocugen pipeline, January 2019)